| Prev Close | 138.84 |
| Day Low/High | 138.56 / 139.50 |
| 52 Wk Low/High | 118.62 / 148.99 |
| Avg Volume | 6.20M |
Johnson & Johnson (JNJ)
138.85
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.66B |
| Market Cap | 371.15B |
| EPS | 5.70 |
| P/E Ratio | 25.89 |
| Div & Yield | 3.80 (2.59%) |
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's Elanco Offload Offers Acquisition Flexibility
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Jim Cramer: The Stock Market's Machine Buyers
These are simply programs where some ETFs and handcrafted baskets are overwhelming both sides of the market.
Jim Cramer: An Absence of Negatives Is a Real Positive
This is what the market looks like when the Fed says nothing and the president isn't ranting about something.
Netflix Is Tonight's Big Report: Here's How I Would Play It
This is a battleground stock that has made big moves in both directions on earnings in the past.
Here's How to Play Adobe on Killer Growth Forecast: Market Recon
Adobe released new guidance for the rest of this year and 2019. With 20% growth in the cards, this name is a buy.
Ignore the Misleading Dow Jones Industrial Average
The DJIA is not accurately reflecting what's going on in the market and will cause you to miss broader weakness that has taken hold.
Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?
The answer is plenty, but you can't trade that.
J&J Stock Is Firming Up Nicely, Stay Long
Let's check some updated charts to see if our strategy is still on track.
Considering Several Trading Short Rentals
As many are aware...I am a believer that in a sea of green, stocks that are red are short trading candidates over the very short term. Conversely, in a sea of red, stocks that are green are long trading candidates over the very near term. Following ...
Jim Cramer: This Is a Rotation, Not a Recession
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Why Pay a Premium for Estee Lauder?
EL's stock is up despite a guidance cut.
Jim Cramer: Could Turkey Prove to Be One More Buying Opportunity?
I always say that you should wait until you get an exogenous reason for stocks to come down and then you should pounce.
Buy Johnson & Johnson, Now Poised to Rally
Johnson & Johnson prices finally look ready to move up.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
The 4 Cheapest 'Dividend Kings' to Buy Today
These stocks offer not only terrific histories of dividend increases, but are also trading at reasonable valuations.
Jim Cramer: How to Pick Stocks When the Market Is Flying Blind
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Johnson & Johnson Is a Great Company, But Be Patient
Bulls see a $158 price target, but JNJ needs a rally to $135.28 for a breakout.
Kevin O'Leary's 'Wonderful' World of ETFs: 3 Great Ways to Follow the Shark
These funds from the Shark Tank star's O'Shares series focus on small-cap dividend names, internet giants and large-cap dividend U.S. dividend stocks.
Rewind: Why Jim Cramer Is Bullish on Johnson & Johnson Shares
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer is bullish on Johnson & Johnson shares.
Jim Cramer: A Pretty Wild Rally In Three Oppositional Groups
How can this be? Let's take a look at the camps so we can figure it out.
Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth
When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
Jim Cramer on Netflix, Goldman Sachs, Bank of America and Johnson & Johnson
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.
Highs (and Lows) of FANG Trading: Market Recon
My Netflix short was a big winner yesterday, but I am also long Amazon and Google, which were hit with pretty strong collateral damage.
Bank Leadership Is Covering Up Some Ugly Market Issues
This quarter Netflix is not going to be the star of earnings season.
Closing Bell: LIVE MARKETS BLOG
The major U.S. indices rose on Friday, closing out the week on a two-day winning streak.
Jim Cramer: This Market Isn't Done Going Higher
We aren't done moving higher even with the president ready to strike at a moment's notice against any of our allies.
Stocks Rise Modestly and 4 Other Stories to Watch Premarket Friday
Happy Friday the 13th! These are the stories moving the market ahead of today's opening bell.
REPLAY: Jim Cramer on Broadcom, CA, Johnson & Johnson, Citigroup & Canopy Growth
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks from the floor of the New York Stock Exchange
